A 130-year-old Lisle, Illinois component maker quietly crossed a strategic threshold in the second quarter of 2026. CTS Corporation, the piezoelectric and electromechanical specialist that once lived and died with the throttle position sensor on a Toyota Camry, now earns roughly 59% of its sales from outside transportation, up from a minority position just a few years ago. The shift in mix is the central narrative of the quarter, and it explains why the share price has held above $50 even as the cyclical anchor softened. The diversification strategy is translating into stronger and more resilient performance, with end-market sales outside transportation now representing the dominant share of the revenue base.
The Q2 readout delivered net sales of $144.8M and operating margin of 18.5%, with diluted EPS climbing from a year earlier. Management raised full-year sales guidance to a range of $565-$585M. Adjusted diluted EPS guidance also lifted, now set at $2.55-$2.70, an upward revision that confirms the diversification thesis is moving faster than the buy side had modeled. Gross margin reached 41.5%, a 270 basis point expansion that reflects richer end-market mix and operational improvements at the ceramic and piezo fabrication lines. The company delivered profitable growth, record margins, and strong cash generation in the period, and management reaffirmed the focus on portfolio transformation.
The risk to the narrative sits in two places: the timing of aerospace and defense contract awards, which depressed that segment in the first half, and the Superfund remediation exposure tied to the Asheville, North Carolina site, where CTS in March agreed in principle to a $7.6M settlement with the EPA. Neither item is a thesis-breaker, but both warrant scrutiny of the multiple. The base case is that adjusted EBITDA margin continues to compound as the medical-industrial mix climbs toward two-thirds of revenue. The bull case layers in faster aerospace awards and a Superfund final settlement that closes the environmental overhang before year-end. The bear case flexes Toyota share erosion and a slower industrial capex cycle that compresses incremental margins on the medical-industrial book.